Notification of dealings by a director/PDMR

Aptamer

09/09/2025 07:00

RNS Number : 4893Y

Aptamer Group PLC

09 September 2025

 

 

9 September 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notification of dealings by a director/PDMR

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces that Dr Adam Hargreaves, Non-Executive Chairman, on 8 September 2025 purchased 5,000,000 ordinary shares of £0.001 each ("Ordinary Shares") in the Company at a price of 1 pence per Ordinary Share, through Pathcelerate Limited.

 

Following this transaction, Dr Adam Hargreaves total beneficial interest in the Company is 175,379,305 Ordinary Shares, representing approximately 6.50% of the Company's issued share capital.

 

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of ordinary shares by directors and other PDMRs in the Company.

 

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Dr Adam Hargreaves(Pathcelerate Limited)
2
Reason for the notification
a)
Position/status
Non-Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Aptamer Group plc
b)
LEI
213800Y4XGH3WJNBE686
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BNRRP542
b)
Nature of the transaction
Purchase of shares
c)
Price(s) and volume(s)
Price 1p
Volume 5,000,000
d)
Aggregated information
- Aggregated volume
5,000,000
- Price
1p
e)
Date of the transaction
8 September 2025
f)
Place of the transaction
London Stock Exchange

 

- Ends -

 

For further information, please contact: 

 

Aptamer Group plc
Dr Arron Tolley, Chief Executive Officer
+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Jade Bayat
+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker
James Pope / Andrew Thacker
+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations
Sarah Hollins
+44 (0) 113 730 3896

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHLPMRTMTAMBJA